Investor FAQs

The Company is incorporated in Stockholm, Sweden

Calliditas was first listed at Nasdaq Stockholm in 2018, and at Nasdaq US in 2020

The fiscal year ends Dec 31

The auditor is Ernst&Young AB

Read more on our Auditor page

Please contact:

Marie Galay, IR Manager
Email: [email protected]
Telephone: +44 79 55 12 98 45

For more information about Calliditas’ commercial product, please visit www.tarpeyo.com

Calliditas is advancing its delayed release formulation of budesonide under the development name “NEFECON®” outside of the USA. Calliditas submitted a Marketing Authorisation Application for NEFECON to the European Medicines Agency in May 2021. If approved, the drug could be available to patients in the European Economic Area (EEA) member states, Switzerland and the UK in 2022.

Calliditas partnered with Everest Medicines to commercialise NEFECON® in Greater China and Singapore in 2019. In July 2021, Calliditas announced a partnership with STADA to commercialise NEFECON in the European Economic Area (EEA) member states, Switzerland and the UK.

The NefIgArd trial is still ongoing, with the full data readout expected in early 2023. Calliditas is also conducting an open label extension trial with NEFECON®.

With its drug candidate setanaxib, a first-in-class NOX1/4 Inhibitor, Calliditas has initiated a Phase 2b/3 adaptive design trial in PBC and will initiate a Phase 2 study in head and neck cancer.